Dana-Farber/Harvard Cancer Center Awarded $12 Million NCI SPORE Grant to Advance Breast Cancer Research

The Dana-Farber/Harvard Cancer Center (DF/HCC)'s Specialized Program of Research Excellence (SPORE) in Breast Cancer, under the leadership of principal investigators Kornelia Polyak, MD, PhD, Professor of Medicine at Dana-Farber; Leif Ellisen, MD, PhD, Program Director of Breast Medical Oncology at Massachusetts General Hospital (MGH), Nancy Lin, MD, Associate Chief, Division of Breast Oncology at Dana-Farber and Geoffrey Shapiro, MD, PhD , Senior Vice President, Developmental Therapeutics at Dana-Farber, has been awarded a highly competitive, federal grant from the National Cancer Institute. The $12 million, five-year award represents a renewal of the DF/HCC’s SPORE in Breast Cancer grant, originally received in 2000, and underscores the investigators’ leadership and innovation in breast cancer research.  

Since launching in 2000, the Breast Cancer SPORE at DF/HCC continues to lead breast cancer research and leave their mark on the field. Investigators regularly advance new therapeutic strategies into clinical trials, reveal key mechanisms of drug resistance, and develop creative and groundbreaking approaches to immunotherapy and precision medicine. The Breast Cancer SPORE excels at facilitating collaborations and connections across disciplines and institutions, training the next generation of breast cancer researchers, and engaging patients and advocates in discovery – as true partners. This work has already shaped clinical practice nationally and are laying the groundwork for future innovations that seek to improve the lives of patients with breast cancer.

Visit the DF/HCC Breast SPORE page here.
Read the Cancer Letter writeup of this announcement here.
Read the Dana-Farber Cancer Institute writeup of this announcement here.
Visit the NCI Page on the DF/HCC Breast SPORE here.